BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the ...
BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient ...
(RTTNews) - scPharmaceuticals Inc. (SCPH) Monday reported positive topline results from the pharmacokinetic study of SCP-111 (furosemide), administered via an autoinjector. The study compared the ...
BURLINGTON, Mass. - scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company, announced positive results from a study of SCP-111, its investigational autoinjector designed to deliver furosemide ...
The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental ...
scPharmaceuticals Inc., a pharmaceutical company, announced positive topline results from the pharmacokinetic (PK) study of SCP-111, an investigational, low volume, pH neutral formulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results